Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Drug Des Devel Ther. 2022 Jun 16;16:1847-1863. doi: 10.2147/DDDT.S361955. eCollection 2022.
Endometrial cancer (EC) is one of the most common gynecological malignancies, especially in postmenopausal women. Echinacoside (ECH) is a major natural bioactive ingredient derived from Cistanches Herba and Echinacea that has a variety of pharmacological effects. However, the efficacy and the mechanism of ECH against EC have not been elucidated yet.
A compound-target-disease network was constructed to explore the potential targets and mechanism of ECH against EC. Molecular docking and in vitro experiments further verified the effect of ECH against EC.
The potential targets of ECH against EC were retrieved from multiple public databases. Then, the protein-protein interaction (PPI) network was constructed to screen hub targets. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed to discover the potential mechanism. Molecular docking was utilized to verify the binding affinity between hub targets and ECH. Finally, in vitro experiments were conducted to demonstrate the anti-EC effect of ECH.
A total of 110 genes were identified as potential targets of ECH against EC. The GO enrichment analysis found that targets were primarily related to oxygen species, apoptosis, and other physiological processes. KEGG pathway analysis showed that PI3K/Akt signaling pathways might play an important role in ECH against EC. Molecular docking indicated that ECH had a significant binding ability with the EGFR, AKT1, ESR1, CASP3, HSP90AA1and MMP9 targets. Results from in vitro experiments revealed that ECH induced apoptosis of Ishikawa and HEC-1-B cells by promoting the arrest of the G2M phase, increasing ROS levels, and decreasing mitochondrial membrane potential (MMP) levels. Furthermore, treatment of ECH significantly reduced the expression levels of PI3K and p-AKT, and the combination of the PI3K inhibitor (LY294002) further enhanced the effects of ECH against EC. The findings suggested that ECH exerted an inhibitory effect on EC cells by inhibiting the PI3K/AKT pathway.
Based on network pharmacology, molecular docking technology and in vitro experiments, we comprehensively clarified the anti-EC efficacy of ECH through multiple targets and signal pathways. Furthermore, we provided a novel idea of Traditional Chinese medicine (TCM) against EC.
子宫内膜癌(EC)是最常见的妇科恶性肿瘤之一,尤其在绝经后妇女中更为常见。松果菊苷(ECH)是一种源自肉苁蓉和紫锥菊的主要天然生物活性成分,具有多种药理作用。然而,ECH 对 EC 的疗效及其机制尚未阐明。
构建化合物-靶标-疾病网络,探讨 ECH 对 EC 的潜在靶标和作用机制。通过分子对接和体外实验进一步验证 ECH 对 EC 的作用。
从多个公共数据库中检索 ECH 治疗 EC 的潜在靶标。然后,构建蛋白质-蛋白质相互作用(PPI)网络,筛选出关键靶标。进行基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析,以发现潜在的作用机制。利用分子对接验证关键靶标与 ECH 的结合亲和力。最后,进行体外实验以验证 ECH 对 EC 的抗 EC 作用。
共鉴定出 110 个 ECH 治疗 EC 的潜在靶标。GO 富集分析发现,这些靶标主要与氧物种、细胞凋亡和其他生理过程有关。KEGG 通路分析表明,PI3K/Akt 信号通路可能在 ECH 治疗 EC 中发挥重要作用。分子对接表明,ECH 与 EGFR、AKT1、ESR1、CASP3、HSP90AA1 和 MMP9 靶标具有显著的结合能力。体外实验结果表明,ECH 通过促进 G2M 期阻滞、增加 ROS 水平和降低线粒体膜电位(MMP)水平,诱导 Ishikawa 和 HEC-1-B 细胞凋亡。此外,ECH 处理显著降低了 PI3K 和 p-AKT 的表达水平,而 PI3K 抑制剂(LY294002)的联合使用进一步增强了 ECH 对 EC 的作用。这些发现表明,ECH 通过抑制 PI3K/AKT 通路对 EC 细胞发挥抑制作用。
基于网络药理学、分子对接技术和体外实验,我们通过多个靶标和信号通路全面阐明了 ECH 对 EC 的抗 EC 作用。此外,我们为中药(TCM)治疗 EC 提供了新的思路。